Bank of America Raises Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $175.00

Ascendis Pharma A/S (NASDAQ:ASND) had its price target raised by Bank of America from $165.00 to $175.00 in a research report report published on Wednesday, Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

A number of other research analysts also recently commented on ASND. Jefferies Financial Group upped their price objective on Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a buy rating in a research note on Tuesday, August 13th. Wells Fargo & Company lowered their price target on shares of Ascendis Pharma A/S from $277.00 to $264.00 and set an overweight rating for the company in a research report on Wednesday. Cantor Fitzgerald cut their price objective on shares of Ascendis Pharma A/S from $173.00 to $170.00 and set an overweight rating on the stock in a research report on Wednesday. Stifel Nicolaus started coverage on shares of Ascendis Pharma A/S in a research note on Friday, May 31st. They set a buy rating and a $200.00 target price for the company. Finally, Evercore ISI upgraded shares of Ascendis Pharma A/S to a strong-buy rating in a research note on Monday, August 26th. Two investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Ascendis Pharma A/S has a consensus rating of Moderate Buy and a consensus price target of $187.08.

Ascendis Pharma A/S Stock Up 0.1 %

Shares of NASDAQ ASND opened at $119.15 on Wednesday. The firm’s 50-day moving average price is $134.38 and its two-hundred day moving average price is $138.20. Ascendis Pharma A/S has a 52-week low of $85.29 and a 52-week high of $161.00. The stock has a market capitalization of $6.94 billion, a P/E ratio of -12.40 and a beta of 0.63.

Institutional Trading of Ascendis Pharma A/S

Hedge funds have recently modified their holdings of the company. Vestal Point Capital LP acquired a new position in Ascendis Pharma A/S in the fourth quarter worth $78,719,000. GSA Capital Partners LLP acquired a new stake in Ascendis Pharma A/S in the 1st quarter valued at about $992,000. Price T Rowe Associates Inc. MD raised its stake in shares of Ascendis Pharma A/S by 23.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock worth $269,374,000 after acquiring an additional 336,976 shares during the last quarter. ADAR1 Capital Management LLC acquired a new position in shares of Ascendis Pharma A/S during the fourth quarter worth approximately $5,779,000. Finally, Perceptive Advisors LLC bought a new stake in shares of Ascendis Pharma A/S during the fourth quarter valued at approximately $16,648,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.